# OnCo record paper-jain-talicabtagene-lancet-haem-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-jain-talicabtagene-lancet-haem-2025" ;
  schema:name "Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study"@en ;
  schema:description "The trial report behind India's first CAR-T therapy: about three in four heavily pretreated patients with lymphoma or leukaemia responded to cells engineered and made in Mumbai."@en ;
  schema:url <https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S2352-3026(24)00377-6>, <https://doi.org/10.1016/S2352-3026(25)00040-7> ;
  schema:sameAs <https://doi.org/10.1016/S2352-3026(24)00377-6> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Jain H, Karulkar A, Kalra D, et al." ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/talicabtagene-autoleucel/> ;
  onco:companies <https://onco.cc/companies/immunoact/> ;
  onco:institutions <https://onco.cc/institutions/tata-memorial/>, <https://onco.cc/institutions/iit-bombay/> ;
  onco:trials <https://onco.cc/trials/talicel-phase-1-2/> ;
  onco:people <https://onco.cc/people/jain-hasmukh/>, <https://onco.cc/people/narula-gaurav/>, <https://onco.cc/people/purwar-rahul/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:journals <https://onco.cc/journals/lancet-haematology/> .